Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03435471 · ClinicalTrials.gov registry record · NA

Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer

A NA study of Head and Neck Cancer and Oropharynx Cancer, sponsored by University of Miami.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03435471: Completed NA study of Head and Neck Cancer and Oropharynx Cancer, sponsored by University of Miami.

NCT03435471 is a NA study of Head and Neck Cancer and Oropharynx Cancer that has completed, run by University of Miami. The registered enrollment target is 30 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03435471, a NA study of Head and Neck Cancer and Oropharynx Cancer, has completed, sponsored by University of Miami.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Clinician directed prophylactic swallowing therapy will improve immediate (four weeks +/- two weeks) and short-term (26 weeks +/- four weeks) post-treatment swallowing function and quality of life versus patient directed home exercises. The purpose of this prospective, interventional, pilot investigation is to determine whether clinician directed swallowing therapy will improve patient swallowing function outcomes and quality of life in the immediate and short-term basis compared to patients receiving standard of care patient directed independent home swallowing therapy. Patient compliance with home exercises programs is reportedly inconsistent. Patients may experience changes in their physical functioning and overall well-being that may impact their ability to follow-through with independent home therapy. Clinician directed swallowing therapy allows for ongoing assessment of changes that may warrant modifying the therapy program in terms of intensity of exercises and/or expectations. This facilitates individualizing the patient's therapy plan to maximize their function and ability to achieve goals. It is anticipated that individualizing swallowing therapy through weekly session will result in improved swallowing function.

Primary Outcome

Swallowing status will be measured using Functional Oral Intake Scale (FOIS). FOIS has a range from 0 (most restrictive) to 7 (least restrictive).

Interventions

  • OTHER Prophylactic Swallowing Home Exercise Program
  • OTHER Clinician-Directed Prophylactic Swallowing Exercises

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-09-17
Est. Completion 2021-01-13
Phase NA
University of Miami

721 total trials

What the finished NCT03435471 record still lists

NCT03435471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower).

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Prophylactic Swallowing Home Exercise Program is the first listed.

NCT03435471 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03435471 about?

NCT03435471 is a clinical study titled "Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer". Clinician directed prophylactic swallowing therapy will improve immediate (four weeks +/- two weeks) and short-term (26 weeks +/- four weeks) post-treatment swallowing function and quality of life versus patient directed home exercises. The purpose of this prospective, interventional, pilot investi...

What is the current status of trial NCT03435471?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-09-17. Estimated completion is 2021-01-13.

What conditions does trial NCT03435471 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Oropharynx Cancer.

What interventions are being tested in trial NCT03435471?

The interventions under investigation include: Prophylactic Swallowing Home Exercise Program (OTHER), Clinician-Directed Prophylactic Swallowing Exercises (OTHER).

Who is sponsoring clinical trial NCT03435471?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03435471 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03435471's enrollment target sits among peer trials

30 174th of 250 higher than 66 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03435471, the US trial registry maintained by the National Library of Medicine. NCT03435471 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.